Selecta Biosciences Reports Third Quarter 2019 Financial Results and Provides Corporate Update
08 nov. 2019 08h00 HE
|
Selecta Biosciences, Inc.
- Compelling preclinical data presented at the European Society of Gene and Cell Therapy Annual Congress demonstrates the potential for redosing in AAV-mediated gene therapy; announced strategic...
Selecta Biosciences Announces Date of Third Quarter 2019 Financial Results Conference Call
01 nov. 2019 08h09 HE
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., Nov. 01, 2019 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies...
Selecta Biosciences to Present Phase 2 Data for SEL-212 in Chronic Refractory Gout at Upcoming 2019 ACR Annual Meeting
24 oct. 2019 08h00 HE
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., Oct. 24, 2019 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies...
Selecta Biosciences Presents New Preclinical Data from its Gene Therapy Program at 2019 ESGCT Annual Congress
23 oct. 2019 10h48 HE
|
Selecta Biosciences, Inc.
Highlights the ability to prevent formation of vector-induced neutralizing antibodies (Nabs) and enable re-administration of AAV vectors in combination with Selecta’s ImmTOR (SVP-Rapamycin)...
Selecta Biosciences to Participate in Two Investor Conferences in October
25 sept. 2019 08h00 HE
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., Sept. 25, 2019 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies...
Selecta Biosciences Appoints Brad Dahms as Chief Financial Officer
04 sept. 2019 08h00 HE
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., Sept. 04, 2019 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies...
Selecta Biosciences to Present at the Janney Healthcare Conference
03 sept. 2019 08h07 HE
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies...
Selecta Biosciences Reports Second Quarter 2019 Financial Results and Provides Corporate Update
08 août 2019 08h00 HE
|
Selecta Biosciences, Inc.
- New strategic partnership with gene therapy leader, AskBio, to jointly develop next-generation AAV-based gene therapies to address the unmet medical need for repeat dosing in patients with rare and...
Selecta Biosciences Combines ImmTOR™ Platform with AskBio’s Industry-Leading Gene Therapy Platform in Strategic Partnership
07 août 2019 07h00 HE
|
Selecta Biosciences, Inc.
WATERTOWN, Mass. and RESEARCH TRIANGLE PARK, N.C., Aug. 07, 2019 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB) and Asklepios BioPharmaceutical, Inc. (AskBio), today announced a...
Selecta Biosciences Announces Date of Second Quarter 2019 Financial Results Conference Call
01 août 2019 08h00 HE
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., Aug. 01, 2019 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies...